<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03034408</url>
  </required_header>
  <id_info>
    <org_study_id>2015-00160</org_study_id>
    <nct_id>NCT03034408</nct_id>
  </id_info>
  <brief_title>Nalmefene, Baclofen and Impulsivity in Subjects With Alcohol Use Disorder and Healthy Control Subjects</brief_title>
  <official_title>Effects of Nalmefene and Baclofen on Impulsivity in Subjects With Alcohol Use Disorder and Healthy Control Subjects: A Randomized, Placebo-controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Prof. Daniele Zullino</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Geneva</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Impulsivity is a central feature of addiction. Nalmefen is an authorized treatment for
      alcohol addiction. Baclofen has empathically been advocated to have some efficacy in this
      indication. The aim of the present study is to test the effect of Nalmefene and Baclofen on
      impulsivity.

      Primary study objective: To examine the effect of Nalmefene and Baclofen on impulsivity (as
      measured by the Stop Signal Task) in subjects with alcohol use disorder and healthy control
      subjects.

      Main secondary study objectives: To examine the effect of Nalmefene and Baclofen on risk
      taking (as measured by the Balloon Analogue Risk Task) and on the preference for small
      immediate rewards over large delayed rewards (as measured by the Delay Discounting Task). To
      compare subjects with alcohol use disorder and healthy control subjects on these tasks.

      Primary study outcome: Stop-signal reaction time in the Stop-Signal Task Main secondary study
      outcomes: Equivalence point in the Delay-Discounting Task and Average number of pumps
      delivered in the Balloon Analogue Risk Task

      Study Design: Randomized, placebo control, cross-over, single-dose
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2016</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in &quot;Stop-signal reaction time&quot; in the Stop-Signal Task</measure>
    <time_frame>0 and 2 hours post-dose</time_frame>
    <description>Before-drug/after-drug difference of the stop-signal reaction time in the Stop Signal Task at Visit 2, Visit 3 and Visit 4.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in &quot;Equivalence point&quot; in the Delay-Discounting Task</measure>
    <time_frame>0 and 2 hours post-dose</time_frame>
    <description>Before-drug/after-drug difference of the Equivalence point&quot; in the Delay-Discounting Task at Visit 2, Visit 3 and Visit 4.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in &quot;Average number of pumps&quot; delivered in the Balloon Analogue Risk Task</measure>
    <time_frame>0 and 2 hours post-dose</time_frame>
    <description>Before-drug/after-drug difference of the &quot;Average number of pumps&quot; delivered in the Balloon Analogue Risk Task at Visit 2, Visit 3 and Visit 4.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Alcohol Use Disorder</condition>
  <arm_group>
    <arm_group_label>Alcohol Use Disorder</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>30 patients with DSM-5 Diagnosis of Alcohol Use Disorder, at least moderate (303.90/F10.20) : Nalmefene 18mg, Baclofen 10mg, Placebo Oral Capsule</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy Control</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>30 sex and age-matched healthy controls : Nalmefene 18mg, Baclofen 10mg, Placebo Oral Capsule</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nalmefene</intervention_name>
    <arm_group_label>Alcohol Use Disorder</arm_group_label>
    <arm_group_label>Healthy Control</arm_group_label>
    <other_name>Selincro</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Baclofen</intervention_name>
    <arm_group_label>Alcohol Use Disorder</arm_group_label>
    <arm_group_label>Healthy Control</arm_group_label>
    <other_name>Lioresal</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Oral Capsule</intervention_name>
    <arm_group_label>Alcohol Use Disorder</arm_group_label>
    <arm_group_label>Healthy Control</arm_group_label>
    <other_name>Mannitol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  30 patients with DSM-5 Diagnosis of Alcohol Use Disorder, at least moderate
             (303.90/F10.20),

          -  30 sex and age-matched healthy controls,

          -  over 18, informed consent.

        Exclusion Criteria:

          -  opiate-treatment,

          -  contra-indications for Nalmefene and/or Baclofen,

          -  unstable psychiatric disorder,

          -  pregnancy,

          -  acute withdrawal syndrome.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniele F Zullino, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Geneva University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Daniele F Zullino, MD</last_name>
    <phone>+41223725750</phone>
    <email>daniele.zullino@hcuge.ch</email>
  </overall_contact>
  <location>
    <facility>
      <name>Service d'Addictologie, Hôpitaux Universitaires de Genève</name>
      <address>
        <city>Geneva</city>
        <zip>1202</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zullino F Daniele, MD</last_name>
      <phone>+41223725750</phone>
      <email>daniele.zullino@hcuge.ch</email>
    </contact>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <link>
    <url>http://www.hug-ge.ch/addictologie/recherche</url>
    <description>website related to the study</description>
  </link>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 3, 2016</study_first_submitted>
  <study_first_submitted_qc>January 25, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2017</study_first_posted>
  <last_update_submitted>January 25, 2017</last_update_submitted>
  <last_update_submitted_qc>January 25, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Geneva</investigator_affiliation>
    <investigator_full_name>Prof. Daniele Zullino</investigator_full_name>
    <investigator_title>Prof.</investigator_title>
  </responsible_party>
  <keyword>Impulsivity</keyword>
  <keyword>Nalmefene</keyword>
  <keyword>Baclofen</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Alcohol Drinking</mesh_term>
    <mesh_term>Impulsive Behavior</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ethanol</mesh_term>
    <mesh_term>Nalmefene</mesh_term>
    <mesh_term>Naltrexone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

